Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)
Liver International · 2026
DOI: 10.1111/liv.70577 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, 2026. Verfasst von Oana Săndulescu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases I, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Hauptthemen laut MEDLINE: Viral Hepatitis Vaccines, Hepatitis, Viral, Human, Disease Eradication. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention, from long‐established immunisation programs to emerging opportunities and unmet needs. This review explores the evolving landscape of hepatitis vaccines against four major hepatotropic viruses. Hepatitis A offers a paradigm of vaccine effectiveness yet shifting epidemiological patterns and immunity gaps in transitional economies call for updated public health approaches. For hepatitis E, the availability of a safe and effective vaccine presents a critical but underutilised opportunity to prevent outbreaks and protect vulnerable populations, particularly in endemic regions and among high‐risk groups. The prevention of hepatitis B relies on decades of success with universal childhood vaccination. Albeit rare, breakthrough infections require more insight into immune memory, viral variants, and strategies for the optimization of long‐term protection. Finally, for hepatitis C, the absence of a vaccine underscores the biological and immunological complexities that have thus far impeded progress toward prevention, even as new technological platforms and cross‐virus insights renew optimism. By integrating epidemiological, immunological, and translational perspectives, this article highlights how vaccines remain central to eliminating viral hepatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases I, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, Romania.
- Academy of Romanian Scientists, Bucharest, Romania.
- Infection Science Forum, Bucharest, Romania.
- Clinical Microbiology, Infection Prevention and Control, Office for Medical Services, Lund, Sweden.
- Division of Medical Microbiology, Department of Laboratory Medicine Lund, Medical Faculty, Lund University, Lund, Sweden.
Zitieren
APA
Săndulescu, O., Şahin, G. Ö., Dudman, S. G., Said, Z. N. A., Mondelli, M. U., & ESCMID Study Group for Viral Hepatitis (ESGVH) (2026). Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH). Liver International. https://doi.org/10.1111/liv.70577
Vancouver
Săndulescu O, Şahin GÖ, Dudman SG, Said ZNA, Mondelli MU, ESCMID Study Group for Viral Hepatitis (ESGVH). Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH). Liver International. 2026. doi:10.1111/liv.70577
BibTeX
@article{Sndulescu2026,
author = {Săndulescu, Oana and Şahin, Gülşen Özkaya and Dudman, Susanne Gjeruldsen and Said, Zeinab Nabil Ahmed and Mondelli, Mario U and ESCMID Study Group for Viral Hepatitis (ESGVH), ESCMID Study Group for Viral Hepatitis (ESGVH)},
title = {Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70577}
}
EUVIMED